Use of Home Spirometry for Steroid Tapering Authors: Zayan Musa, Carson Tyler Moss, Carlos Daniel Hernandez Borges, Husham Sharifi, Joe Hsu Published: 2026 ABSTRACT ABSTRACTOrganising pneumonia (OP) is a late, non‐infectious pulmonary complication that occurs following haematopoietic cell transplant (HCT) and may be associated with chronic graft‐versus‐host‐disease (cGVHD). Treatment typically involves protracted courses of corticosteroids that are associated with dose‐limiting adverse effects and pulmonary exacerbations upon corticosteroid tapering. Here, we describe the case of a 43‐year‐old male with OP associated with cGVHD who experienced difficulty tapering prednisone, complicated by frequent OP exacerbations. Weekly home spirometry was used to closely monitor trends in pulmonary function and help successfully guide the prednisone taper. Ultimately, prednisone dose was reduced by 80% while maintaining clinical and functional stability.Keywords: chronic graft‐versus‐host‐disease, haematopoietic cell transplant, home spirometry, organising pneumonia, pulmonary function tests Introduction Organising pneumonia (OP) is a late, non‐infectious lung complication after haematopoietic cell transplantation (HCT) with many aetiologies including chronic graft‐versus‐host‐disease (cGVHD). OP is characterized by the proliferation of fibroblasts and granulation tissue in the alveolar spaces and results in significant morbidity and mortality [1]. A presumptive diagnosis of OP following HCT (HCT‐OP) has been suggested to include clinical, radiologic and physiologic criteria, requiring: allogeneic HCT history; concurrent or prior GVHD in any organ; chest CT findings consistent with OP; restrictive physiology on pulmonary function testing (PFT) with reduced forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO), but preserved typically FEV1/FVC ratio; and exclusion of infection [1]. Lung biopsy is often deferred unless in cases of diagnostic uncertainty or disease refractory to treatment. Characteristic CT findings include bilateral, asymmetric consolidation and ground‐glass opacities in a sub‐pleural and/or peribronchovascular distribution with lower lobe predominance in most cases; the reverse‐halo sign and nodules/masses occur less frequently [2]. Treatment typically includes high‐dose corticosteroids and pulmonary exacerbations can occur in up to 30%–50% of patients [1]. Initial prednisone dosing ranges from 0.5 mg/kg/day in non‐hypoxemic patients to 1–2 mg/kg/day in severe hypoxemia, with tapering by 5 mg every 2 weeks. Exacerbations often occur during tapering of corticosteroids [1]. However, long‐term, high‐dose corticosteroid treatment may be associated with adverse effects, including weight gain, hyperglycemia, osteoporosis and immunosuppression [1]. This report highlights the challenges in managing HCT‐OP, particularly, minimising the iatrogenic effects of therapy and the benefit of home spirometry to provide real‐time testing of lung function. Case Report A 43‐year‐old male with myelodysplastic syndrome underwent allogeneic HCT, with post‐transplantation course complicated by cGVHD affecting the mouth, eyes, gastrointestinal tract and liver. The patient presented in January 2020 with dyspnea and pulmonary ground‐glass opacities on CT scan consistent with HCT‐OP (Figure 1A). His pre‐transplant PFT in 2017 showed no evidence of abnormality; however, PFT at time of illness showed restrictive physiology: 45% percent predicted forced expiratory volume in 1 s (ppFEV1), 39% percent predicted forced vital capacity (ppFVC), 0.88 FEV1/FVC ratio, with 38% percent predicted diffusion capacity of carbon monoxide (ppDLCO). Medication review excluded drug‐induced pneumonitis, which can mimic HCT‐OP and has been associated with antimicrobials (amphotericin, nitrofurantoin), antiepileptics (carbamazepine, phenytoin), cardiovascular agents (amiodarone) and immunotherapy (bleomycin, methotrexate, cyclophosphamide) [3]. Clinical course of patient with recurrent exacerbations of organising pneumonia after haematopoietic cell transplant. (A) Chest computed tomography (CT) at time of OP diagnosis (Month 1) demonstrating characteristic radiologic findings of bilateral subpleural ground‐glass opacities (yellow arrowheads) and reverse‐halo sign (central ground‐glass opacity surrounded by a peripheral crescent of consolidation, characteristic of OP; red circle). (B) Chest CT at time of disease stability (Month 50) following steroid taper, demonstrating interval resolution of ground‐glass opacification. (C) Longitudinal spirometric and steroid dose data. Left y‐axis: percent predicted FEV1 from laboratory spirometry (ppFEV1; blue line), percent predicted FVC from laboratory spirometry (ppFVC; red line) and ppFEV1 from home spirometry (green line). Right y‐axis: prednisone daily dose in mg/day (grey shading). Timepoints corresponding to CT imaging denoted in Panels A (*) and B (**). Month 0 denotes pre‐transplant baseline; Month 1 denotes OP diagnosis. The axis break between Months 27 and 28 reflects change in x‐axis scale following initiation of home spirometry. Upon diagnosis, prednisone 40 mg daily was initiated leading to improvement in dyspnoea, exercise tolerance and measures of pulmonary function (FEV1 and FVC). Treatment was complicated by steroid‐induced hyperglycemia and weight gain. Dose reduction to 30 mg coincided with increased fatigue, lip discoloration, xerosis and pleuritic chest pain. A prolonged taper to 7 mg resulted in dyspnoea and pleuritic chest pain; hospitalisation for HCT‐OP flare and escalation of prednisone to 40 mg was required. Steroid sparing agents—ruxolitinib and mycophenolate—were trialled but failed to decrease prednisone dosing or improve symptoms. In March 2022, he enrolled in a clinical trial with Axatilimab, an inhibitor of macrophage and monocyte colony‐stimulating factor‐1 receptor (CSF‐1R) [4]. Prednisone use reduced by 33% while on trial, however, was discontinued after 9 months due to infusion reactions. A progressive enlarging pulmonary nodule prompted bronchoscopy with transbronchial cryo‐biopsy, which demonstrated mononuclear cell interstitial pneumonitis with granulation tissue plugs consistent with OP; infectious studies were negative. Over 26 months, clinic‐based PFTs proved insufficient to guide steroid tapering. Home spirometry monitoring was initiated in March 2022, with weekly testing thereafter. Decreases in home spirometry ppFEV1 were treated with nebulized budesonide to facilitate weaning of systemic corticosteroids. Throughout the home spirometry directed taper, one escalation of prednisone to 25 mg occurred due to infections with rhinovirus and Influenza A in December 2022. By November 2023, despite reducing prednisone to 10 mg and discontinuation of nebulized budesonide, he demonstrated improving exercise tolerance, FVC and FEV1. A CT chest scan at this time showed near complete radiologic resolution of HCT‐OP (Figure 1B). As of March 2026, the dose was further reduced to 7 mg, while preserving disease stability (Figure 1C). Discussion To our knowledge, this is the first report of home spirometry used in the management of HCT‐OP. Prior to home spirometry, the patient was monitored via exercise capacity, oxygen saturation and symptoms (e.g., dyspnoea, pleuritic chest pain). These measures lacked sensitivity for timely intervention, as significant symptoms often emerged only after disease had progressed to require hospitalisation. Spirometry provides objective data that can help guide therapies, however, formal testing is limited by infrequent measurements, patient burden and facility capabilities. In other conditions such as sarcoidosis, home spirometry has facilitated personalised prednisone treatment plans [5]. Handheld, wireless devices enable remote surveillance and early detection of early pulmonary complications in high‐risk populations. This modality has been shown to closely correlate with formal spirometry studies in asthma, cystic fibrosis and chronic obstructive pulmonary disease [6]. Although some systems underpredict FEV1, its use allows for close monitoring of pulmonary trajectory, thereby detecting early lung disease and improving health outcomes [7]. Following HCT, it has been shown to be reliable for following cGVHD patients with bronchiolitis obliterans syndrome (BOS) (Table 1) [7, 8, 9, 10, 11]. Currently, the National Institutes of Health recommends spirometry every 3 months after the diagnosis of cGVHD for up to 2 years [12], yet this strategy may be too infrequent to detect pre‐clinical changes in flares of OP. As there are no current publications that describe the use of home spirometry for HCT‐OP, further investigation is needed to validate its use as an effective tool for exacerbation monitoring. Our case highlights handheld spirometry as a feasible, accessible adjunct to lab‐based pulmonary testing. TABLE 1Summary of studies using home spirometry for hematopoietic cell transplant recipients.ReferencesDevicePopulation N InterventionMajor findingsCheng et al. [4]KoKo Peak Pro‐6, Ferraris Respiratory/PiKo‐6, Pulmonary Data ServicesAllogeneic haematopoietic cell transplant (HCT) recipients from December 2005 and February 2010437 Clinical spirometry at pre‐transplant, Day 80 and 1‐year post‐transplant. Weekly home spirometry for 1‐year post‐transplant. Strong correlation between in‐clinic and home spirometry (r = 0.931) indicates feasibility of at‐home spirometry as a screening tool for detecting subclinical changes. 1‐year FEV1 bias (−0.10 L [−0.77, 0.56]) supports its utility for early screening, but not as a replacement for lab‐based PFTs. While FEV1 correlates well, negative bias shows that home spirometry tends to underestimate lab values. Loiseau, Clémence et al. [6]Spirotel, M‐Elect, FranceAllogeneic HCT recipients from June 2001 to November 2008110 Clinical spirometry once pre‐transplant for correlation with home spirometry. Home Spirometry twice weekly for 18 months started at 3 months post‐transplant Adherence rate was low at 35.5%. Home spirometry detected 13 cases of BOS, including 3 asymptomatic, demonstrating its potential for the identification of early bronchiolitis obliterans syndrome (BOS) in adherent patients. Turner et al. [8]Bluetooth‐compatible home spirometer (GoSpiro, Monitored Therapeutics Inc)Allogeneic HCT recipients with chronic graft‐versus‐host‐disease (cGVHD) or FEV1 decline after allogeneic HCT46 Clinical spirometry recommended every 3 months Weekly home spirometry for 52 weeks Strong correlation between home and clinical FEV1 (bias of 0.123 L [−0.294, 0.54]), indicates that home spirometry effectively monitors patients with cGVHD at high risk of developing BOS. Home spirometry detected 9 out of 12 patients diagnosed or suspected of having BOS through FEV1 decline. Sheshadri et al. [5]Bluetooth‐compatible home spirometer (GoSpiro, Monitored Therapeutics Inc)Allogeneic HCT recipients 100 days post‐transplantation between October 2016 and June 201851 Home spirometry up to 9 months with no required frequency Follow‐up at 1, 3, 6 and 9 months via survey questions Patient‐reported outcomes demonstrates that home spirometry is efficient, user‐friendly and aids in symptom management and early detection of diseases such as BOS.Towe et al. [7]Bluetooth‐compatible home spirometer (GoSpiro, Monitored Therapeutics Inc)Autologous and allogeneic HCT recipients ≤ 24 years of age37Home spirometry from 100 days post‐transplant to 6 months. Home spirometry is an appropriate method to monitor pulmonary function in paediatric HCT patients. Adherence rates align with other home testing for children with intricate medical needs. Note: A literature review summarizing the efficacy of home spirometry in monitoring pulmonary function in hematopoietic cell transplant recipients across various study populations and handheld home spirometry devices. Summary of studies using home spirometry for hematopoietic cell transplant recipients. Clinical spirometry at pre‐transplant, Day 80 and 1‐year post‐transplant. Weekly home spirometry for 1‐year post‐transplant. Strong correlation between in‐clinic and home spirometry (r = 0.931) indicates feasibility of at‐home spirometry as a screening tool for detecting subclinical changes. 1‐year FEV1 bias (−0.10 L [−0.77, 0.56]) supports its utility for early screening, but not as a replacement for lab‐based PFTs. While FEV1 correlates well, negative bias shows that home spirometry tends to underestimate lab values. Clinical spirometry once pre‐transplant for correlation with home spirometry. Home Spirometry twice weekly for 18 months started at 3 months post‐transplant Adherence rate was low at 35.5%. Home spirometry detected 13 cases of BOS, including 3 asymptomatic, demonstrating its potential for the identification of early bronchiolitis obliterans syndrome (BOS) in adherent patients. Clinical spirometry recommended every 3 months Weekly home spirometry for 52 weeks Strong correlation between home and clinical FEV1 (bias of 0.123 L [−0.294, 0.54]), indicates that home spirometry effectively monitors patients with cGVHD at high risk of developing BOS. Home spirometry detected 9 out of 12 patients diagnosed or suspected of having BOS through FEV1 decline. Home spirometry up to 9 months with no required frequency Follow‐up at 1, 3, 6 and 9 months via survey questions Home spirometry is an appropriate method to monitor pulmonary function in paediatric HCT patients. Adherence rates align with other home testing for children with intricate medical needs. Note: A literature review summarizing the efficacy of home spirometry in monitoring pulmonary function in hematopoietic cell transplant recipients across various study populations and handheld home spirometry devices. Author Contributions Z.M., C.T.M., C.H.B, H.S. and J.L.H. contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. Z.M. and C.T.M. are in medical school and residency in different institutions but work as research staff at Stanford in the Hsu Lab. Funding J.L.H. is funded by NIH/NHLBI R01HL157414 and NIH/NCAT R21TR005507. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images and attest that the form used to obtain consent from the patient complies with the Journal requirements as outlined in the author guidelines. Conflicts of Interest The authors declare no conflicts of interest. Musa Z., Moss C. T., Borges C. D. H., Sharifi H., and Hsu J., “Use of Home Spirometry for Steroid Tapering,” Respirology Case Reports 14, no. 6 (2026): e70607, 10.1002/rcr2.70607. Associate Editor: Philip Eng Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.